Lenalidomide for Non-Hodgkin's Lymphoma
This trial is testing the combination of lenalidomide and rituximab to see if it is more effective in treating NHL than lenalidomide alone.
- Non-Hodgkin Lymphoma
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Is this study still enrolling new participants?
"Data from clinicaltrials.gov suggests that this particular trial is not currently recruiting patients. The study was initially posted on April 1st, 2014 but was last edited on October 25th, 2020. There are 2419 other trials seeking patients at the moment."
Are there any dangers associated with Rituximab?
"There is some clinical evidence in support of Rituximab's efficacy, as well as multiple rounds of safety data, so it received a score of 3."
What is the general research consensus on Rituximab's effectiveness?
"Rituximab was first studied in 1993 at National Institutes of Health Clinical Center. So far, there have been 1105 completed studies with 628 trials actively recruiting patients. Many of these locations are based out of Park Ridge, Illinois."
What are some of Rituximab's primary functions?
"Rituximab is most often used to treat diffuse large b-cell lymphoma (dlbcl), however, it has also been found effective in treating other conditions such as at least two prior systemic chemotherapy regimens, b-cell lymphomas, and polyangium."
How many individuals are involved in this clinical trial?
"This particular study is no longer looking for volunteers. It was originally posted on April 1st, 2014 but has not been updated since October 25th, 2022. However, there are currently 1791 trials actively recruiting participants with lymphoma and 628 trials involving Rituximab that are still admitting patients."
Can you tell me how many different hospitals are participating in this clinical trial?
"There are 100 sites participating in this study, including Oncology Specialists, PC in Park Ridge, Sparrow Hospital and Health System in Lansing, Local Institution - 050 in Bolivar, and other locations."